WP
FATE icon

Westmount Partners’s Fate Therapeutics FATE Stock Holding History

Westmount Partners’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.3K Hold
10,098
– – 0.01% 274
2026
Q1 		$12.1K Hold
10,098
– – ﹤0.01% 264
2025
Q4 		$9.92K Hold
10,098
– – ﹤0.01% 246
2025
Q3 		$12.6K Buy
+10,098
New +$10.9K ﹤0.01% 244

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Westmount Partners's FATE Position: Q2 2026 in Review

Westmount Partners held its Fate Therapeutics (FATE) position steady in Q2 2026 at 10,098 shares worth $27.3K. The position accounts for 0.01% of the portfolio, ranked #274.

Westmount Partners first reported a position in FATE in Q3 2025 and has held it in 4 quarters since. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Westmount Partners held 10,098 shares of Fate Therapeutics worth $27.3K as of Q2 2026.
  • Westmount Partners left its Fate Therapeutics share count unchanged in Q2 2026.
  • Fate Therapeutics made up 0.01% of Westmount Partners's portfolio in Q2 2026, its #274 holding.
  • Westmount Partners first reported a position in Fate Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Westmount Partners's 13F filing for Q2 2026, filed 7 Jul 2026.